-

Carlsmed Launches Cutting-Edge Digital Production Line, Revolutionizing Spine Surgery

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, a commercial-stage medical technology company and pioneer of the personalized spine surgery market, today announced the successful launch of its state-of-the-art digital production line. This innovative technology will enable the company to deliver its aprevo® personalized spinal fusion implants to hospitals in less than ten days.

“This advancement is more than just a technical achievement,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “The reduced lead time makes aprevo® available for surgeries with shorter scheduling windows, increasing addressable procedures and furthering our commitment to making personalized surgery accessible to every patient who needs it.”

Carlsmed’s current portfolio of patient-specific devices is indicated for use in lumbar spine fusion surgery. The company is developing patient-specific implants for cervical spine fusion surgery and received FDA Breakthrough Device designation for cervical fusions earlier this year. The launch of aprevo® for cervical fusions is expected by the end of 2025.

“The aprevo® implants were crucial for my recovery,” said Renee Schreiner, a patient who received the aprevo® procedure. “When my surgeon told me that personalized spine surgery was available to me, I immediately felt more comfortable choosing to have surgery. Knowing that my implant was designed just for me made all the difference.”

Carlsmed is dedicated to innovation and excellence in personalized healthcare, ensuring that it meets the unique needs of every individual it serves. Clinical publications show significant improvements in patient outcomes for aprevo® personalized procedures compared to traditional spine fusion surgery.

About Carlsmed

Carlsmed is a commercial stage medical technology company and leader of the personalized spine surgery market. aprevo® is the only commercially available custom made anatomically designed interbody for spine fusion surgery.

Contacts

For media and investor inquiries, please contact Jodi Allen at jodi@carlsmed.com.

Carlsmed


Release Versions

Contacts

For media and investor inquiries, please contact Jodi Allen at jodi@carlsmed.com.

Social Media Profiles
More News From Carlsmed

Carlsmed Announces FDA Clearance for aprevo® Cervical Breakthrough Fusion Device

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed” or the “Company”) a MedTech company pioneering AI-enabled personalized spine surgery, today announced FDA 510(k) clearance for the aprevo® Cervical ACDF Interbody System. This milestone underscores Carlsmed’s commitment to advancing patient-specific spine surgery solutions that enhance outcomes and surgical precision. The FDA previously granted Breakthrough Device designation for Carlsmed’s aprevo® technology for the treatment of pat...

Carlsmed Adds Industry Veteran, Kevin O’Boyle, to Board of Directors

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, the leader in personalized spine surgery, announced that Kevin O’Boyle has joined its Board of Directors and will serve as the Chair of the Audit Committee. Mr. O’Boyle previously served as a director of seven publicly traded companies, including Wright Medical Group (WMGI), GenMark Diagnostics (GNMK) and Zeltiq (ZLTQ). In addition to Carlsmed, he currently serves on the board of Nevro (NVRO). Mr. O’Boyle has over 20 years of executive management exp...

Carlsmed Announces Favorable Medicare Reimbursement Decision for Spinal Fusions with Custom-Made Anatomically Designed Devices

CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, the leader in personalized spine surgery, announced today that in the Hospital Inpatient Prospective Payment System Final Rule for fiscal year 2025, the Centers for Medicare & Medicaid Services (CMS) assigned spinal fusion cases with aprevo® custom-made anatomically designed interbody fusion devices to the highest level of the new spinal fusion Medicare Severity-Diagnosis Related Groups (MS-DRGs) it created. The new assignments and payment rates...
Back to Newsroom